Pfizer reafffirms 2026 guidance after CFO transition announcement

Investing.com -- Pfizer Inc. confirmed its financial outlook for 2026 on Thursday after announcing the transition of its Chief Financial Officer.

The pharmaceutical company reiterated its revenue projection between $59.5 billion and $62.5 billion for the full year. Pfizer also maintained its adjusted diluted earnings per share forecast in a range of $2.80 to $3.00.

The company first provided this guidance on December 16, 2025, and confirmed it again during its first-quarter earnings call on May 5, 2026.

Chief Financial Officer Dave Denton will leave Pfizer on August 15 to take a position in the consumer goods sector.

Cecile Guegan will serve as interim chief financial officer starting August 16. Guegan currently holds the position of senior vice president for finance in Pfizer's global biopharmaceutical business.

Pfizer said it will search for a permanent CFO both inside and outside the company.

You May Also Be Interested In

• Northrim BanCorp (NRIM) Tops Q2 EPS by 6c
• Kalanick’s Atoms raises $1.7B in a16z-led round for industrial AI
• James Hardie raises Q1 FY2027 revenue outlook above prior guidance